Which orphan drug made headlines in 2019 when its manufacturer set a $2.1 million price tag, making it the most expensive treatment in the world at that time?

The pharmaceutical industry employs various pricing strategies, but perhaps none more controversial than those for orphan drugs - medications developed for rare diseases affecting fewer than 200,000 people. These treatments often come with eye-watering price tags justified by R&D costs and limited patient populations. This poll tests your knowledge about a landmark orphan drug pricing case that changed industry practices.

This is a live public trivia poll on AIPolls.Net. Vote and see real-time results.

Zolgensma (onasemnogene abeparvovec) - Novartis gene therapy for spinal muscular atrophy
Soliris (eculizumab) - Alexion treatment for paroxysmal nocturnal hemoglobinuria
Ravicti (glycerol phenylbutyrate) - Horizon Therapeutics medication for urea cycle disorders
Actimmune (interferon gamma-1b) - Horizon Therapeutics treatment for chronic granulomatous disease